Abstract
Introduction/BackgroundWith the approval of the first poly-(adenosine diphosphate-ribose) polymerase inhibitor (PARPi), olaparib therapy has demonstrated efficacy in first-line (1L) maintenance for Breast Cancer gene mutated (BRCAm) advanced ovarian cancer (AOC)...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
